The committee discussed a biologics license application (BLA) for Evenity (romosozumab) injection, submitted by Amgen, for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant of other available osteoporosis therapy.. A majority of the committee, 16of 19 members, voted that the overall benefit/risk profile of romosozumab is acceptable to support approval for the proposed osteoporosis use.
Back to All Events
Earlier Event: January 11
Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee
Later Event: January 17
Endocrinologic and Metabolic Drugs Advisory Committee